MM120

Phase 3Small molecule

DDefinium Therapeutics US, Inc.

MM120 is one of 67 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

Generalized Anxiety DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

115 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Zoloft

VViatris Specialty LLC

Approved

15 2

Effexor

WWyeth-Lederle Vaccines

Approved

8 3

Ulotaront

IIntra-Cellular Therapies, Inc.

Approved

6 4

Mirapex

Boehringer Ingelheim

Approved

2 5

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Approved

—6

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 7

Ketalar

Boehringer Ingelheim

Phase 3

5 8

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 9

Clozaril

LLife Extension Foundation Inc.

Phase 3

1 10

Psilocybin

COMPASS Pathways

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Major Depressive Disorder

NCT06941844

Q2 2027

Phase 3Active, not recruiting

Generalized Anxiety Disorder

NCT06741228

Phase 3Active, not recruiting

Generalized Anxiety Disorder

NCT06809595

Clinical

Trials by Indication[1]

Generalized Anxiety Disorder2 trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06741228·214 enrolled

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06809595·245 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

Completed·DDefinium Therapeutics US, Inc.·Phase 2·NCT05200936·53 enrolled

Anxiety1 trial

A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Completed·DDefinium Therapeutics US, Inc.·Phase 2·NCT05407064·198 enrolled

Major Depressive Disorder1 trial

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Emerge

Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06941844·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MM120. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MM120 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MM120. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Definium Therapeutics US, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDefinium Therapeutics US, Inc.

MM120

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Generalized Anxiety Disorder2 trials

Safety and Efficacy1 trial

Anxiety1 trial

Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News